ReviewVirulence2014
A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens.
Review in Virulence, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 264 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
264 citing papers in PubMed, 1 synthesis or guideline pooled it, 584 citations in OpenAlex.
- The Potential of Bacteriophage Therapy as an Alternative Treatment Approach for Antibiotic-Resistant Infections.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2024Pooled it
- Genotoxicity and sub-chronic oral toxicity of a blend of bacteriophage for animal feeds.Toxicology reports · 2026Article
- Phage Therapy Enhanced by Using Engineered Bacteriophages: A Powerful Antibacterial Tool to Address the Dilemma Posed by Multidrug-Resistant Bacterial Infections.International journal of molecular sciences · 2026Review
- Salmonella infection in chickens: pathogen, pathogenesis, and dietary non-drug feed additives as alternatives to antibiotics - a comprehensive review.Folia microbiologica · 2026Review
- Bacteriophage cocktails and bacterial coevolution: a systematic review of resistance prevention strategies against multidrug-resistant pathogens in sewage water.Iranian journal of microbiology · 2026Article
- Unraveling a new Klebsiella phage KP47 against Klebsiella spp.BMC microbiology · 2026Article
- Effect of Bacteriophage Administration Route on Phage Localization in a Rat MRSA Implant-Associated Infection Model.Antibiotics (Basel, Switzerland) · 2026Article
- ICP1 bacteriophage treatment antagonizes colonization of the zebrafish larval intestine byMicrobiology spectrum · 2026Article
- Robust detection in faeces andVeterinary and animal science · 2026Article
- Article
- Human Gut Phageome Analysis Uncovers Thousands of Highly Modular Endolysins.MicrobiologyOpen · 2026Article
- Isolation and characterization of broad-rangeMicrobiology (Reading, England) · 2026Article
- Isolation and genomic characterization of a lytic bacteriophage against multidrug-resistant Proteus mirabilis.Applied microbiology and biotechnology · 2026Article
- Impact of phage therapy in post-weaning piglets challenged with ETEC strain in a controlled minitrial.Porcine health management · 2026Article
- Innovative Approaches to Combat Antimicrobial Resistance: A Review of Emerging Therapies and Technologies.Probiotics and antimicrobial proteins · 2026Review
- Synthetic Biology of Plants and Microbes for Agriculture, Environment, and Future Applications.Chemical reviews · 2026Review
- Bacteriophage Therapy: Overcoming Antimicrobial Resistance Through Advanced Delivery Methods.Molecules (Basel, Switzerland) · 2026Review
- Phage Therapy at the Crossroads Between Clinical Promise and Regulatory Challenge.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Antimicrobial Resistance: How Can We Overcome the Problem?Antibiotics (Basel, Switzerland) · 2026Review
- Bacterial meningitis in adults: therapeutic challenges in the era of antibiotic resistance and the potential of bacteriophages and associated by products.Frontiers in cellular and infection microbiology · 2026Review
204 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The seemingly inexorable spread of antibiotic resistance genes among microbial pathogens now threatens the long-term viability of our current antimicrobial therapy to treat severe bacterial infections such as sepsis. Antibiotic resistance is reaching a crisis situation in some bacterial pathogens where few therapeutic alternatives remain and pan-resistant strains are becoming more prevalent. Non-antibiotic therapies to treat bacterial infections are now under serious consideration and one possible option is the therapeutic use of specific phage particles that target bacterial pathogens. Bacteriophage therapy has essentially been re-discovered by modern medicine after widespread use of phage therapy in the pre-antibiotic era lost favor, at least in Western countries, after the introduction of antibiotics. We review the current therapeutic rationale and clinical experience with phage therapy as a treatment for invasive bacterial infection as novel alternative to antimicrobial chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.